Diagnosis, Treatment, Follow-up, and Persistence of Trichomonas vaginalis in Women 45 Years and Older According to HIV Status: A 10-Year Retrospective Cohort
- 5 March 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 47 (5) , 332-337
Abstract
Background: Trichomonas vaginalis is a common treatable sexually transmitted infection among older women. Persistent T. vaginalis infection after treatment is common among women with human immunodeficiency virus (HIV). We sought to determine if HIV-negative women were as likely as women with HIV to have persistent T. vaginalis infection. Methods: We performed a retrospective cohort study of women 45 years or older with T. vaginalis infection. We evaluated differences in persistent T. vaginalis infection according to HIV status using χ2 analysis. We performed regression analyses to describe factors associated with persistent and recurrent infection in older women. Results: Over a 10-year study period, we identified 282 women with T. vaginalis, 46 with HIV. Most women (240, 86%) were treated in accordance with 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases treatment guidelines. Half of the women (144, 53%) had a repeat T. vaginalis test 90 to 365 days after treatment, and one third had persistent infection (39/125, 31%). Persistent infection was similar between women with HIV and HIV-negative women treated according to Centers for Disease Control recommendations (17% vs 33%, P = 0.3). When adjusting for age and incidental diagnosis, tobacco use was associated with an increased risk of more than 1 or recurrent T. vaginalis infection during the study period (adjusted odds ratio, 2.8; 95% confidence interval, 1.5–4.9). Conclusions: The HIV status did not affect persistent T. vaginalis infection in women 45 years or older. Given over one third of women have a positive test within a year after the recommended treatment, our data support repeat testing in women 45 years and older treated for T. vaginalis.Keywords
This publication has 17 references indexed in Scilit:
- Unexpected High Rates of Persistent Trichomonas vaginalis Infection in a Retrospective Cohort of Treated Pregnant WomenSexually Transmitted Diseases, 2019
- Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trialThe Lancet Infectious Diseases, 2018
- Trichomonas vaginalis is most frequently detected in women at the age of peri-/premenopause: an unusual pattern for a sexually transmitted pathogenAmerican Journal of Obstetrics and Gynecology, 2018
- Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty IncidentMMWR. Recommendations and Reports, 2015
- Correlation of Leukorrhea and Trichomonas vaginalis InfectionJournal of Clinical Microbiology, 2013
- A Prospective Cohort Study Comparing the Effect of Single-Dose 2 g Metronidazole on Trichomonas vaginalis Infection in HIV-Seropositive Versus HIV-Seronegative WomenSexually Transmitted Diseases, 2013
- A Trich-y QuestionSexually Transmitted Diseases, 2013
- Prevalence and Correlates of Trichomonas vaginalis Infection Among Female US Federal Prison InmatesSexually Transmitted Diseases, 2010
- The Prevalence of Trichomonas vaginalis Infection among Reproductive-Age Women in the United States, 2001-2004Clinical Infectious Diseases, 2007
- Prevalence, Incidence, and Persistence or Recurrence of Trichomoniasis among Human Immunodeficiency Virus (HIV)–Positive Women and among HIV‐Negative Women at High Risk for HIV InfectionClinical Infectious Diseases, 2002